The answer, according to a team of researchers from China Three Gorges University and Yichang hospitals led by Yixing Li, Dehui Liu, Ruixue Qin, Xingchang Li, and Mei Li, is uncomfortable for anyone hoping that diet holds the key. Their models could explain a moderate share of the between-country variation in thyroid cancer incidence—the best-performing stacking ensemble reached an out-of-fold R² of 0.613 with a rank correlation of 0.901 between predicted and observed rates—but almost all of that predictive power came from socioeconomic indicators, not food. Nine development variables alone, drawn from the Human Development Index and its life expectancy, education, and income sub-indices, achieved an R² of 0.609. A diet-only model built from 140 dietary variables managed just 0.284. And when the researchers added the entire dietary block to the socioeconomic baseline, the improvement was statistically indistinguishable from zero in every model family they tested.

The technical rigor behind that negative result is what makes it credible. The team integrated four open databases—GLOBOCAN 2022 cancer estimates, FAOSTAT Food Balance Sheets covering 113 food items from 2010 to 2022, the UNDP Human Development Report 2025 statistical annex, and WHO obesity prevalence—into a single harmonized dataset spanning 163 countries and 155 variables. Thirteen regression algorithms were evaluated inside a fully nested cross-validation framework: multiple imputation, standardization, four-method consensus feature selection, and hyperparameter tuning were all refitted from scratch within the training partition of every outer fold, so no held-out country ever influenced the model that predicted it. Confidence intervals were obtained by resampling countries with replacement across 2,000 bootstrap replicates, propagating the true sampling variability of the 163 units of analysis rather than the quirks of arbitrary fold boundaries.

The researchers also tested whether their models could generalize beyond geographic similarity. Because neighboring countries resemble one another in diet, registry infrastructure, and screening practice, random cross-validation folds are not truly independent. When entire world regions were held out in turn, the models preserved the rank ordering of countries reasonably well—pooled rank correlation of 0.813—but lost much of their ability to reproduce absolute rates. The models transport the ordering of countries across regions better than their level, which the authors interpret as a sign that part of the apparent accuracy under random validation comes from regional peers in the training set. Cyprus and South Korea, the two highest-incidence countries and both documented examples of screening-driven overdiagnosis, were consistently underpredicted, suggesting that unmeasured diagnostic intensity explains the shortfall better than dietary composition does.

But the study is not purely a story about wealth. When the researchers moved from prediction to confounder-adjusted association analysis, a specific dietary signal did survive scrutiny. Under an extended adjustment set containing the HDI, its three sub-indices, obesity prevalence, and region fixed effects, and after Benjamini–Hochberg correction across all comparisons, five variables retained positive partial correlations with incidence: seafood supply (partial r = 0.196, q = 0.031), dairy supply (0.198, q = 0.031), the iodine-rich food availability index (0.224, q = 0.026), the animal-to-plant protein ratio (0.260, q = 0.011), and mollusks (0.203, q = 0.031). Plant protein, which showed an inverse unadjusted association, did not survive multiplicity correction—a null result the authors state plainly rather than dress up as a protective effect.

The iodine-rich food availability index is the study’s most robust finding, and the team interrogated it with unusual care. The index combines national per-capita supply of seafood, dairy, and eggs—the three food groups identified by WHO/FAO as the principal dietary sources of iodine worldwide—weighted as seafood plus 0.10 times dairy plus 0.05 times eggs. Because any such weighting is an analytical choice rather than a measurement, the researchers rebuilt the composite under four alternative schemes, including equal-weighted, standardized, and iodine-content-weighted variants. The association held across all of them, with extended-adjustment partial correlations ranging from 0.196 to 0.256. Entered separately, seafood and dairy each retained a significant association while eggs did not, despite a comparable unadjusted correlation. And in a specificity test, an iodine-poor animal-origin food index built from bovine, pig, poultry, and mutton and goat meat had the largest unadjusted correlation of any variable examined (ρ = 0.309) but failed to survive adjustment (partial r = 0.102, q = 0.198 under the extended set). The animal-origin foods poorest in iodine are precisely the ones whose association vanishes once confounders are removed.

How much of the seafood–incidence correlation actually tracks national development? A descriptive path decomposition, following the Baron and Kenny framework in a purely ecological sense, partitioned the total association into an HDI-tracking component and a residual direct term. The HDI pathway accounted for 50.2 percent of the seafood–incidence correlation, with a bootstrap interval running from 16 to 90 percent—so the point estimate should be read as roughly half, with wide uncertainty, rather than as a precise partition. The residual component is consistent with the adjusted association analysis, in which seafood retains a positive partial correlation after adjustment for development, obesity, and geography. But the authors make no causal claim about it: the analysis is a cross-sectional ecological quantity, and unmeasured confounders including radiation exposure history, national iodization programs, and genetic susceptibility remain plausible explanations.

The secondary mortality analysis adds an important interpretive check. Thyroid cancer is highly survivable, and its incidence is strongly influenced by diagnostic intensity, while its mortality is comparatively insensitive to the detection of small, indolent, screen-detected tumors. The dietary variables followed the same ordering for mortality as for incidence, so the incidence associations are not a pattern that appears only in a detection-sensitive outcome. But associations with the mortality-to-incidence ratio were close to zero or negative—HDI at ρ = 0.053 and seafood at ρ = 0.065. Since that ratio is comparatively insensitive to detection intensity while incidence is not, this contrast indicates that the ecological correlations operate substantially through case detection rather than through case fatality. The authors are explicit that this is a consistency check on the primary findings, not an independent result.

The study also benchmarked a high-dimensional deep tabular model, DynaTab, against the conventional estimators under the identical nested protocol. DynaTab reached a pooled out-of-fold R² of 0.626, statistically comparable to the stacking ensemble and random forest, with intervals that overlap almost entirely. A purpose-built high-dimensional model therefore matches, rather than overturns, the predictive accuracy achievable on these data—and it does not alter the block-wise finding, which concerns which variable groups carry the between-country signal rather than which model extracts it. In a sensitivity classification analysis, Extra Trees reached an AUC of 0.932 at the median split, though the authors caution that dichotomizing a skewed continuous rate makes the contrast artificially easy and should not be read as evidence of clinical utility.

What the iodine-rich food availability index does and does not measure is the study’s most important caveat. The index is a measure of national food-group availability, not of iodine intake, iodine status, or iodine exposure in any individual. Food balance sheets describe supply rather than consumption and do not capture waste, spoilage, or unequal distribution. The iodine content of a given food group varies substantially with production method, soil and water iodine content, feed composition, and processing—a kilogram of milk in one country is not nutritionally equivalent to a kilogram in another. Most important, the largest single determinant of iodine intake in most countries is not any of these food groups but salt iodization, which FAOSTAT does not measure and which could not be adjusted for at the country level. The authors describe their result throughout as an association between the availability of iodine-rich food groups and thyroid cancer incidence, and never as an association with iodine exposure.

The methodological lesson is as valuable as the dietary hypothesis. In these data, adding 140 dietary variables to nine development indicators produced no improvement in prediction that the bootstrap intervals could distinguish from zero, while the model importance rankings were dominated by the income and life expectancy sub-indices. Ecological machine learning studies that report dietary predictors of cancer burden without an explicit socioeconomic baseline, a leakage-free validation design, and multiplicity control risk attributing to diet what belongs to development. The positive implication concerns the specific hypothesis the study was designed to test: the availability of iodine-dense animal-origin food groups retains a positive association with thyroid cancer incidence after adjustment for development, metabolic status, and geography, after correction for multiple comparisons, and after the construction of the index is varied and tested against an iodine-poor negative control. That is a hypothesis worth taking to designs that can test it—cohorts with validated dietary assessment and measured urinary iodine, direct measures of national thyroid imaging utilization and salt iodization coverage, Mendelian randomization to address confounding by design, and longitudinal panel models in which exposure is observed before outcome. Until such evidence exists, these findings remain ecological correlates and should not be translated into individual dietary advice.

Subject of Research: Ecological machine learning analysis of global thyroid cancer incidence in relation to dietary and socioeconomic factors

Article Title: Global thyroid cancer incidence in relation to dietary and socioeconomic factors: an ecological machine learning study

Article References: Li, Y., Liu, D., Qin, R., Li, X., & Li, M. (2026). Global thyroid cancer incidence in relation to dietary and socioeconomic factors: an ecological machine learning study. Frontiers in Oncology, 16, Article 1842508. https://doi.org/10.3389/fonc.2026.1842508

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1842508

Keywords: thyroid cancer, machine learning, ecological study, GLOBOCAN, FAOSTAT, iodine-rich food availability, seafood, Human Development Index, overdiagnosis, path decomposition, Frontiers in Oncology, cancer epidemiology

The research, published in BMC Medical Imaging, was led by Kyu-Chong Lee and Kyung-Sik Ahn of Korea University Anam Hospital in Seoul, together with colleagues from several Korean medical centers. The team set out to answer a deceptively simple question: when a shoulder MRI shows abnormalities of the joint capsule, what do those abnormalities actually mean? Adhesive capsulitis has long been associated with characteristic changes in two specific regions of the shoulder joint, the rotator interval and the axillary pouch. The rotator interval is a triangular space between the supraspinatus and subscapularis tendons through which the long head of the biceps tendon passes, while the axillary pouch is the redundant fold of capsule at the lower part of the joint that allows the arm to lift overhead. In classic frozen shoulder, both regions typically show thickening, edema, and inflammation.

To investigate, the researchers conducted a retrospective analysis of 483 adults who underwent shoulder MRI between January and December 2020. Two musculoskeletal radiologists independently reviewed each scan, assessing abnormalities in the rotator interval and the axillary pouch, as well as tears of four key tendons: the supraspinatus, the infraspinatus, the subscapularis, and the long head of the biceps tendon. The team defined radiologic capsular abnormality, abbreviated RCA, as the presence of abnormalities in both the rotator interval and the axillary pouch simultaneously. They then used univariable and multivariable logistic regression analyses to identify which clinical and imaging factors were associated with RCA, and performed subgroup analyses comparing four patient groups: those with no capsular abnormality, those with isolated axillary pouch abnormality, those with isolated rotator interval abnormality, and those with full RCA, adjusting for age where appropriate.

The headline finding was striking. Of the 483 patients studied, 234, or 48.45 percent, had radiologic capsular abnormality. In other words, nearly one in every two shoulders scanned showed the capsular changes that many radiologists and clinicians associate with frozen shoulder. Yet clinically diagnosed adhesive capsulitis was present in only 45 patients, or 9.32 percent of the cohort. Of those 45 patients, 43 did indeed have RCA, confirming that the imaging finding is sensitive for the disease. But the reverse is emphatically not true: the overwhelming majority of patients with RCA, more than four out of five, did not have a clinical diagnosis of adhesive capsulitis. The imaging finding, in isolation, is simply not specific enough to serve as a diagnosis.

The regression analyses revealed a web of associations that complicate the picture further. Older age was independently associated with higher odds of RCA, with each additional year of age raising the odds by roughly five percent, an odds ratio of 1.05 with a 95 percent confidence interval of 1.03 to 1.07 and a p-value below 0.001. This makes biological sense, since the joint capsule, like every other soft tissue in the body, undergoes degenerative change over time. A capsule that looks thickened or edematous in a 65-year-old may simply reflect the accumulated wear of decades rather than an active inflammatory disorder. Any diagnostic framework that treats capsular abnormality as synonymous with frozen shoulder must therefore account for the age of the patient, or risk labeling normal age-related change as pathology.

Tendon tears added another layer of complexity. Tears of the subscapularis tendon, one of the four muscles that make up the rotator cuff, were positively associated with RCA. Patients with Lafosse type I subscapularis tears, the mildest grade, had 1.82 times the odds of RCA compared with those without such tears, while those with type II or higher tears had 2.15 times the odds, both statistically significant results. The long head of the biceps tendon, which runs directly through the rotator interval, also emerged as relevant: in subgroup analyses, isolated rotator interval abnormality was associated with a higher prevalence of both subscapularis and biceps tendon tears than no capsular abnormality, even after adjusting for age. This suggests that inflammation or degeneration in the rotator interval often reflects pathology of the tendons that traverse it, rather than a primary capsular disease.

Perhaps most intriguingly, tears of the supraspinatus and infraspinatus tendons, the two most commonly torn rotator cuff tendons, showed the opposite relationship: they were negatively associated with RCA. Patients with these tears were less likely to show capsular abnormalities than patients without them. The authors interpret this finding as consistent with the traditional concept of adhesive capsulitis as a diagnosis of exclusion, a condition diagnosed only after other shoulder pathologies have been ruled out. In practical terms, a shoulder dominated by a large supraspinatus or infraspinatus tear appears less likely to harbor the capsular changes of frozen shoulder, perhaps because the two conditions represent distinct biological processes that do not readily coexist, or because the mechanical picture of a cuff tear overshadows and excludes the capsular one.

The clinical implications of the study are considerable. If nearly half of shoulder MRI scans show capsular abnormalities but only about nine percent of patients have frozen shoulder, then any radiology report that flags capsular abnormality without careful qualification invites overdiagnosis. A patient told that their MRI shows findings consistent with adhesive capsulitis may undergo months of stretching programs, corticosteroid injections, or even capsular distension procedures that address the wrong problem, while the true culprit, perhaps a subscapularis tear or biceps tendon pathology, goes untreated. The authors argue that the term radiologic capsular abnormality itself should be used in reports, precisely because it describes an imaging observation without asserting a clinical diagnosis, and that particular caution is warranted in older patients and in those with subscapularis or biceps tendon pathology.

The study does have limitations inherent to its design. It was retrospective, drawing on patients who had already been referred for shoulder MRI at a single Korean institution, which may limit generalizability to other populations. The clinical diagnosis of adhesive capsulitis was extracted from existing records rather than standardized prospectively, and the researchers note that the article was published initially as an early citable version subject to further edits. Still, the size of the cohort, the independent double reading by two musculoskeletal radiologists, the multivariable statistical framework, and the age-adjusted subgroup analyses give the findings substantial weight. The work was supported by a grant from the National Research Foundation of Korea, and the authors declared no competing relationships with companies whose products might relate to the subject matter.

For patients and clinicians alike, the message is ultimately one of humility about what imaging can and cannot tell us. MRI is a magnificent tool for revealing the anatomy of the shoulder in exquisite detail, but anatomy is not destiny, and a thickened capsule on a scan is a finding, not a verdict. Frozen shoulder remains a clinical diagnosis, rooted in a patient’s history of progressive pain and profound restriction of both active and passive motion, and it should be confirmed by examination rather than inferred from a radiology report. As this study makes clear, the capsule that lights up on MRI may be telling a story about age, about a torn subscapularis tendon, or about an inflamed biceps pulley, and only careful clinical correlation can determine which story is true. In an era when imaging findings increasingly drive diagnostic decisions, the humble conclusion that a scan must never replace the physical examination has rarely been more vividly illustrated.

Subject of Research: Radiologic capsular abnormalities on shoulder MRI and their association with rotator cuff and biceps tendon tears in the diagnosis of adhesive capsulitis

Article Title: Radiologic capsular abnormalities on shoulder MRI: associations with rotator cuff and biceps tendon tears and implications for the diagnosis of adhesive capsulitis

Article References: Lee, K.-C., Ahn, K.-S., Kim, S., Kang, C. H., Jeong, W. K., Kang, W. Y., Kim, B. H., & Shim, E. (2026). Radiologic capsular abnormalities on shoulder MRI: associations with rotator cuff and biceps tendon tears and implications for the diagnosis of adhesive capsulitis. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02895-y

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02895-y

Keywords: shoulder MRI, adhesive capsulitis, frozen shoulder, rotator cuff tear, subscapularis tendon, biceps tendon, rotator interval, axillary pouch, radiologic capsular abnormality, musculoskeletal radiology, overdiagnosis, BMC Medical Imaging

The research, published in JNCI, the Journal of the National Cancer Institute, is a meta-analysis that brings together data from all eight randomised controlled trials of mammography screening ever conducted: the New York Health Insurance Plan trial, the Malmö trial, the Two-County trial, the Edinburgh trial, the Canadian National Breast Screening Study, the Stockholm trial, the Gothenburg trial and the UK Age trial. Rather than treating each trial as an isolated source of truth, the team reanalysed the pooled evidence against a real-world benchmark, using two Danish regional screening programmes as a reference population. The comparison included both invasive breast cancer and ductal carcinoma in situ, the non-invasive condition often picked up through calcifications on mammograms.

The central finding is striking in its simplicity. When the researchers accounted for the temporal dynamics of screening, the excess number of breast cancer cases detected in the randomised trials closely matched what would be expected in a Danish screening population, where overdiagnosis is estimated to be below five percent. In other words, the apparent surplus of cancers in the trials, which has long been cited as proof that overdiagnosis is a substantial problem, looks far more like the ordinary lead-time effect of finding cancers earlier than they otherwise would have been found.

Understanding why earlier estimates were so high requires a technical detour into how screening changes the timing of diagnosis. When a screening programme is introduced, the number of breast cancer diagnoses initially rises sharply, because cancers are detected earlier than they would have been without screening. Over time, this initial surge should be followed by a compensatory drop, as some of the cancers counted in the early period would otherwise have been diagnosed later in the absence of screening. If researchers fail to take this pattern into account, the temporary increase can be mistaken for overdiagnosis, inflating the estimate considerably.

Professor Elsebeth Lynge, professor emerita at the Department of Public Health at the University of Copenhagen, explained the mechanics behind the distortion. She noted that the pattern can also be affected if women in either the screening or control groups continue to undergo screening after the trials had ended, which was common in practice. Contamination of this kind blurs the boundary between the compared groups and can make the control group’s later diagnoses look like a shortfall rather than a delay. The Danish experience offered a natural laboratory for disentangling these effects, because organised screening was introduced in some Danish regions 17 years before others, allowing the researchers to observe how breast cancer diagnoses changed both when screening was introduced and over the longer term.

By comparing breast cancer incidence at identical timepoints in the trials and in Danish routine screening data, the team could examine how similar the observed patterns were and what that similarity implies for overdiagnosis estimates. The alignment between trial data and routine programme data suggests that the trials, when interpreted in their full temporal context, are consistent with overdiagnosis of less than five percent rather than with estimates approaching 50 percent. Matejka Rebolj, senior epidemiologist at Queen Mary University of London, said that some previous high estimates, which influenced screening guidelines and patient communication, were based on evidence gathered before trial data had fully matured.

The analysis also corrected for three structural differences between the trials that can skew overdiagnosis calculations. The first was whether women in the control groups were themselves screened, either after the trial ended or following the introduction of routine programmes, which erodes the contrast between screened and unscreened populations. The second was the number of screening rounds offered in each group, since more rounds provide more opportunities to detect cancers early and shift diagnoses forward in time. The third was the length of follow-up, because a longer observation period allows time for cancers detected early through screening to be diagnosed later in the control group, which is exactly what the lead-time model predicts. After accounting for these differences in screening intensity and follow-up between the groups, the results point to overdiagnosis being substantially less common than previously believed.

The definition of overdiagnosis itself deserves attention, because it is broader than many people assume. It occurs when screening detects a cancer that would never have become life-threatening or caused symptoms during a woman’s lifetime, meaning that without screening she would never have known she had it. It can also include women who die from other causes shortly after a breast cancer diagnosis, since poor health or limited life expectancy means these women were unlikely to benefit from early detection in the first place, as treating the cancer had little chance of improving their health or prolonging their lives. Distinguishing genuine overdiagnosis from cancers that were simply found earlier is therefore one of the hardest measurement problems in screening research, and it is precisely the problem the Danish reference data helped solve.

For Sisse Helle Njor, professor at the University of Southern Denmark and Lillebælt Hospital, the motivation was to bring together all the randomised evidence for a clearer picture. She observed that randomised trials have often been cited as evidence that overdiagnosis is a substantial problem, but that this interpretation is not as straightforward as it may seem. Her conclusion for women is direct: most women will not develop breast cancer, but the study offers reassurance that the benefits of detecting breast cancer early and preventing premature death will outweigh the small risk of unnecessary treatment. Accurate information about how often benefits and harms occur is essential for women weighing whether to attend screening, and the new figures suggest that the balance tilts more favourably than earlier communications implied.

The implications extend beyond the clinic into public health policy. Overdiagnosis estimates have shaped screening guidelines, invitation letters and the international debate about population-based mammography for decades, and figures as high as one in two screen-detected cancers have fuelled scepticism about organised programmes. If the matured trial data support estimates below five percent, the framework for communicating risk to invited women may need revision, and the researchers hope their analysis will provide a basis for a more realistic interpretation of the evidence. The work was supported by the Novo Nordisk Foundation and Cancer Research UK, and its publication in a leading oncology journal signals that the long-running controversy over mammography’s harms may be entering a more settled phase, one in which the fear of unnecessary treatment no longer overshadows the demonstrated capacity of screening to prevent deaths from breast cancer.

Subject of Research: Overdiagnosis in mammography screening estimated through a meta-analysis of randomised trials benchmarked against Danish screening data

Article Title: New analysis points to low overdiagnosis in breast cancer screening

Article References: New analysis points to low overdiagnosis in breast cancer screening. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: breast cancer, mammography screening, overdiagnosis, meta-analysis, randomised controlled trials, lead-time bias, Danish screening programmes, ductal carcinoma in situ, cancer epidemiology, screening guidelines, JNCI, public health

The review, led by Muhammad Danyal Ahsan and colleagues at Weill Cornell Medicine, was preregistered with PROSPERO and conducted according to the PRISMA 2020 reporting standard. The team searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials from their inception through August 2025, screening 18,231 abstracts to identify 17 original research studies published between 2005 and 2024. The studies came from eight countries, with Germany contributing nine of the seventeen, and sample sizes ranged from 22 to 7,287 participants. Critically, the researchers only included studies of people who had no established indication for the scan, excluding patients with known hereditary cancer syndromes, people undergoing cancer staging or recurrence surveillance, and studies that selectively reported results from a single organ system.

The headline numbers are striking. Across the pooled data, only 16.9 percent of scanned individuals had no findings reported, while 78.0 percent had at least one finding. That sounds alarming until the nature of those findings is examined. The most common abnormalities were degenerative spinal disease in 22.0 percent of scans, subcortical cysts in 15.4 percent, and bone marrow edema in 6.2 percent, conditions that are ubiquitous in aging populations and rarely change clinical management when discovered incidentally. The authors estimate that roughly 62 to 67 percent of people undergoing whole-body MRI without a medical indication will receive findings that are not actionable at all.

A smaller but clinically meaningful fraction of scans did flag something requiring attention. Non-malignant actionable findings, defined as non-cancerous abnormalities that prompted laboratory testing, additional imaging, or procedural follow-up, were reported in 14.8 percent of screened individuals. These were most frequently located in the gastrointestinal system, the musculoskeletal system, and the lymphatic or vascular system. The most common specific actionable findings were hepatic steatosis, or fatty liver, in 8.8 percent, pulmonary nodules in 4.8 percent, and uterine fibroids in 4.3 percent. Among the people with such findings, 58.2 percent went on to pursue additional laboratory work or imaging, and 20.8 percent underwent a subsequent procedure such as endoscopy, biopsy, resection, or surgery.

Herein lies the central problem the review exposes: none of the included studies reported the results of that downstream evaluation. Because diagnostic resolution was never documented, the authors could not calculate false-positive rates, overdiagnosis rates, or any measure of whether the follow-up testing ultimately helped or harmed patients. This is a fundamental gap for a screening technology. Screening is only justified when it demonstrably improves clinical outcomes, and the history of medicine is littered with tests that found plenty of abnormalities without extending a single life. Prostate-specific antigen screening and routine diabetes screening in asymptomatic adults, for example, have not proven effective at reducing all-cause mortality, despite detecting real biochemical and metabolic signals.

The cancer detection numbers offer a more nuanced picture. Among the 4,463 participants in the eleven studies that reported pathologically confirmed oncologic outcomes, malignancy was detected in 1.4 percent, with a 95 percent confidence interval of 0.9 to 2.2 percent. The most common cancers found were genitourinary tumors, accounting for 21.8 percent of detections, followed by cancers of the female reproductive system at 19.5 percent and gastrointestinal cancers at 16.5 percent. Notably, the authors point out that roughly 60 percent of the malignancies discovered were in organ systems for which the US Preventive Services Task Force offers no Grade A or B screening recommendation, since current guidelines cover only breast, cervical, colon, and lung cancers. Fewer than 20 percent of US cancers are diagnosed through existing screening programs, which is precisely the gap that multi-organ scanning hopes to fill.

For context, the pooled malignancy yield of whole-body MRI sits within or above the per-examination detection rates of some recommended screening tests. Mammography detects roughly 0.2 to 0.8 percent of cancers per screening round, and colonoscopy detects approximately 0.14 to 0.20 percent. But the authors are careful to emphasize that diagnostic yield alone establishes nothing about clinical benefit. A scan that finds more cancers is not automatically a scan that saves lives; the detected cancers must be ones that would have become lethal without early detection, and the harms of chasing false positives and indolent lesions must be weighed against any mortality reduction. Those calculations simply cannot be made with the current evidence.

The methodological quality of the underlying literature is another major caveat. None of the seventeen included studies was free from risk of bias across all domains when assessed with Joanna Briggs Institute tools, and limitations included concerns about sampling, sample size, and confounding. Statistical heterogeneity between studies was extreme, with I-squared values exceeding 90 percent across most analyses, reflecting differences in the use of contrast agents, diffusion-weighted imaging, vascular protocols, body coverage, thresholds for calling a finding actionable, and outcome definitions. The confidence intervals around the pooled estimates are correspondingly wide; the 95 percent interval for the proportion of scans with any finding spans from 44.9 to 93.9 percent. A funnel plot for the malignancy analyses also showed asymmetry consistent with publication bias or selective reporting, meaning studies that found more cancers may have been more likely to be published.

Generalizability is a further concern. All of the included studies came from non-US healthcare systems in East Asia, Western Europe, and the Middle East, and several involved employer-sponsored, private, or otherwise selected cohorts rather than representative community samples. The pooled cohort was 64.9 percent male, no studies reported race and ethnicity data, and only seven of the seventeen studies explicitly described their populations as asymptomatic. Meanwhile, the commercial landscape that the review is meant to inform is dominated by direct-to-consumer services such as Prenuvo and Function Health, which charge approximately 500 to 3,000 dollars per scan with variable protocols and are often bundled with additional clinical assessments. Marketing campaigns and celebrity endorsements have amplified public interest, yet no professional society, including the American College of Radiology, the USPSTF, or the National Comprehensive Cancer Network, endorses whole-body MRI for the general population.

The authors argue that the technology itself is not the problem; the evidence base is. Whole-body MRI is radiation-free, images multiple organ systems in a single session, and could theoretically address real barriers to preventive care, since organ-specific screening requires multiple visits, is sometimes invasive, and suffers from suboptimal adherence. Advances in artificial intelligence may further reduce acquisition time and standardize interpretation, and the authors suggest that a consensus reporting taxonomy extending the oncologic ONCO-RADS system to cardiovascular, musculoskeletal, and metabolic abnormalities could reduce variability and unnecessary follow-up. But until high-quality observational studies or randomized controlled trials track patients from initial finding through downstream workup to hard outcomes such as morbidity, mortality, overdiagnosis, and cost, the review concludes that most whole-body MRI examinations in people without a medical indication reveal either nothing or nothing that matters, and the clinical value of the scan remains an open question rather than a settled fact.

Subject of Research: Diagnostic yield of whole-body MRI as a multi-disease screening tool in people without an evidence-based indication

Article Title: The Diagnostic Yield of Whole-Body MRI as a Multi-disease Screening Modality: A Systematic Review and Meta-analysis

Article References: Ahsan, M. D., Frontera, N., Gurram, A., Sharaf, S., Qazi, M., Patel, D., Yang, K., Gioia, S., Murray, I. R., McGonigle, R., Guniganti, P., Dodelzon, K., Ma, X., Kierans, A. S., Diamond, L. C., Godwin, K., Shih, G., Sabuncu, M., Lantos, J., … Sharaf, R. N. (2026). The Diagnostic Yield of Whole-Body MRI as a Multi-disease Screening Modality: A Systematic Review and Meta-analysis. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10802-y

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10802-y

Keywords: whole-body MRI, screening, diagnostic yield, meta-analysis, overdiagnosis, cancer detection, incidental findings, preventive medicine, medical imaging, false positives, systematic review, direct-to-consumer health

The study, published in the journal Cancer Causes & Control, was led by Neill Bates of the Department of Academic Affairs at the Brody School of Medicine at East Carolina University, together with urologist Michael Blute Jr., epidemiologist Dmitry Tumin, and family physician Parker Barnwell Jr. The research team set out to answer a deceptively simple question: after the US Preventive Services Task Force issued its landmark 2018 guideline recommending that men aged 55 to 69 make individualized decisions about PSA screening through shared decision-making with their clinicians, did rural and urban men in the eligible age range end up receiving the test and participating in those discussions at comparable rates? The question matters because the 2018 guideline made the screening decision fundamentally conversational rather than automatic, and any barrier to meaningful patient–physician dialogue—such as shorter visits, physician shortages, or weaker primary care infrastructure in rural areas—could in theory translate into measurable disparities.

To investigate, the team turned to the National Health Interview Survey, a nationally representative household survey conducted by the National Center for Health Statistics at the Centers for Disease Control and Prevention. They pooled three cycles of the survey—2019, 2021, and 2023—focusing on men aged 55 and older. Men with a personal history of prostate cancer were excluded, since screening behavior is obviously different for those who have already been diagnosed, as were respondents with missing data on the key variables. The final analytic sample included 15,393 eligible respondents, a large enough pool to support statistically meaningful national estimates once the survey’s complex sampling design was accounted for. After applying the appropriate sampling weights, the researchers estimated that roughly 18 percent of American men in this age group resided in rural areas, a reminder that rural populations constitute a substantial share of the aging male population most affected by prostate cancer screening policy.

The researchers examined three distinct outcomes. The first was whether a man had ever received a PSA test in his lifetime, a measure of cumulative exposure to screening. The second was whether he had received a PSA test within the past 12 months, a closer proxy for current screening behavior in the post-2018 guideline era. The third, assessed only in the 2019 survey cycle, was participation in shared decision-making—that is, whether a clinician had engaged the patient in a discussion of the potential benefits and uncertainties of PSA testing before the test was ordered. This third measure is the most direct window into whether the 2018 guideline’s central mechanism, the informed conversation, is actually reaching patients outside major urban centers.

The headline numbers paint a picture of widespread but incomplete screening engagement. Sixty-one percent of men in the sample reported having received a PSA test at some point in their lives, 39 percent reported testing within the previous year, and among respondents to the 2019 cycle, 48 percent reported having participated in shared decision-making about the test. In other words, even in the post-guideline era, fewer than half of the men facing a screening decision described having had the kind of informed discussion that the US Preventive Services Task Force considers essential. That finding alone is noteworthy, and it holds across both rural and urban populations.

When the team fitted multivariable regression models that adjusted for the survey’s complex design and weighting, the expected rural–urban divide simply failed to materialize. For ever having received a PSA test, the adjusted odds ratio comparing rural and urban men was 0.96, with a 95 percent confidence interval of 0.85 to 1.09 and a p-value of 0.552—statistically indistinguishable from no difference. For testing within the past 12 months, the adjusted odds ratio was likewise 0.96 (95 percent confidence interval 0.85 to 1.07, p = 0.454). And for participation in shared decision-making, the adjusted odds ratio was 0.95 (95 percent confidence interval 0.78 to 1.15, p = 0.586). Across all three outcomes, the confidence intervals straddled the null value comfortably, indicating that whatever differences exist between rural and urban men in this dataset, they are small enough to be explained by random sampling variation.

The authors are careful about how these results should be interpreted, and their caution is instructive. One possibility is that the findings reflect a genuine convergence: following the 2018 guideline, screening conversations and PSA testing may have declined or leveled off similarly in both settings, erasing rural–urban gaps that might have existed earlier. Previous research had documented sharp drops in PSA testing after the Task Force’s controversial 2012 grade D recommendation against routine screening, and studies of the 2018 update found ongoing shifts in testing patterns, but few had examined those patterns specifically through a rural–urban lens at the national level. International evidence from New Zealand and Australia had suggested that remoteness of residence does influence PSA testing patterns, and American studies in regions such as Appalachia had documented more aggressive prostate cancer presentations in rural populations, making the absence of a disparity in screening behavior genuinely unexpected.

A second interpretation, which the authors highlight, involves the COVID-19 pandemic. Two of the three survey cycles included in the analysis—2021 and 2023—captured periods during and after unprecedented disruptions to routine medical care. National data from mid-2020 showed that large fractions of American adults delayed or avoided medical care because of pandemic-related concerns, and subsequent research documented declines in multiple preventive screenings, with some evidence that the disruptions disproportionately affected already disadvantaged groups. If preventive care utilization broadly collapsed during the pandemic years, the rural–urban contrast in PSA testing could have been compressed by a common denominator of reduced access, rather than by equitable improvement. The authors note that their findings might reflect declining preventive care utilization during the COVID-19 pandemic, or similarly low levels of testing and shared decision-making in both populations—two very different explanations with very different implications for policy.

The deeper concern raised by the study may therefore be less about geography than about the low absolute levels of shared decision-making itself. If only about half of eligible men report discussing PSA testing with a clinician before being tested, and that proportion is similar in cities and in the countryside, then the 2018 guideline’s ambition of individualized, informed screening choices is falling short everywhere. Prior studies have found that shared decision-making for PSA testing remains underutilized nationally and that its occurrence varies with patient, physician, and practice-level factors. Prostate cancer screening carries a well-documented tension: PSA testing has contributed to declines in prostate cancer mortality, yet it also generates false positives and detects slow-growing tumors that might never have caused harm, exposing men to biopsies and treatments with lasting side effects. Navigating that trade-off is precisely what shared decision-making is designed to accomplish, and its uneven uptake is a quality-of-care problem that transcends the rural–urban divide.

For clinicians and health systems, the study’s message is twofold. First, rural men in the post-2018 era do not appear to be systematically excluded from PSA screening or screening discussions relative to urban men, at least in self-reported national survey data—a finding that should temper assumptions of inevitable rural disadvantage in this specific domain. Second, and more soberingly, the quality of the screening decision itself appears suboptimal nationwide, with substantial room to improve whether patients live in Greenville, North Carolina, or Manhattan. Because the analysis relied on self-reported survey data, recall and reporting biases cannot be excluded, and the cross-sectional design cannot establish causality or track individual trajectories over time. Still, with a nationally representative sample spanning three survey cycles and rigorous adjustment for the sampling design, the study offers one of the clearest post-guideline snapshots to date of who is getting tested and who is being brought into the conversation. As health systems work to restore preventive care in the pandemic’s aftermath, the findings suggest that efforts to promote genuinely informed prostate cancer screening decisions should target all communities—not only those historically assumed to be left behind.

Subject of Research: Rural–urban disparities in prostate-specific antigen testing and shared decision-making among US men following the 2018 USPSTF prostate cancer screening guidelines

Article Title: Rural–urban disparities in prostate-specific antigen testing and shared decision-making in the US

Article References: Bates, N., Blute, M., Jr., Tumin, D., & Barnwell, P., Jr. (2026). Rural–urban disparities in prostate-specific antigen testing and shared decision-making in the US. Cancer Causes & Control, 37(9), Article 155. https://doi.org/10.1007/s10552-026-02243-z

Image Credits: AI Generated

DOI: 10.1007/s10552-026-02243-z

Keywords: prostate cancer, PSA testing, shared decision-making, rural health, health disparities, cancer screening, USPSTF guidelines, National Health Interview Survey, preventive care, COVID-19 pandemic, overdiagnosis, urology

The authors build their case from a series of revealing examples drawn from British screening history. The UK National Screening Committee recommended against population-based prostate cancer screening, concluding that while screening prevented prostate cancer deaths, it also caused harm through overdiagnosis and overtreatment, leaving some men with urinary incontinence or erectile dysfunction. In reaching that conclusion, the committee made a value judgement about how to weigh extended life against morbidity — and, the authors note, it assumed without evidence that individual men would share its values. Meanwhile, when Wales extended the cervical screening interval for women aged 25 to 49 from three years to five in 2022, a scientifically defensible decision triggered a public outcry and a petition signed by more than a million people, prompting England to delay the same change until July 2025.

Bowel screening illustrates how resources quietly shape supposedly clinical thresholds. The faecal immunochemical test, or FIT, applies a binary cut-off to the amount of blood in a stool sample, and that cut-off ranges from 8.5 to 150 micrograms of haemoglobin per gram of faeces across programmes, largely to manage colonoscopy capacity. Historically, Wales used a threshold of 150, England 120 and Scotland 80 micrograms per gram — meaning a result deemed normal in England could have triggered a colonoscopy just across the Scottish border. The stakes of delay are also stark: randomised trials showed guaiac-based faecal occult blood testing reduced colorectal cancer mortality as early as 1996, yet England’s screening programme only completed roll-out in 2010. Screening now prevents roughly 2,000 colorectal cancer deaths annually in England; had it rolled out in 2000, the authors estimate some 20,000 premature deaths could have been averted.

To make sense of such cases, Sasieni and John adapt five principles for decision-making under uncertainty — proportionality, justice, autonomy, feasibility and adaptability — into a framework specifically for cancer screening. Their central claim is that policymakers suffer from an asymmetry of fear: they worry intensely about false-positive decisions, such as introducing a screening programme that turns out to do more harm than good, while largely ignoring false-negative decisions, in which beneficial programmes are delayed or withheld. Because committees periodically revisit recommendations, a cautious ‘not yet’ feels reversible and safe. But delay has consequences that can be quantified even without certainty. If prostate screening in men aged 50 to 65 reduces prostate cancer mortality by 25 percent over 15 years, a two-decade implementation delay could translate into around 20,000 avoidable deaths in the UK. Conversely, had multimodal ovarian cancer screening been introduced for women aged 50 to 74 before the definitive UKCTOCS trial results, roughly 7,000 women each year might have undergone unnecessary surgery. Both sides of the ledger can be estimated, the authors argue, and should be before decisions are made.

The principle of justice exposes another hidden cost of slowness: inequality. Wealthy and well-educated people frequently obtain screening privately long before public programmes roll out. In the United States, colonoscopy use is 50 percent higher in the wealthiest socioeconomic quintile than in the poorest. In England, prostate-specific antigen testing is 25 percent lower in the most deprived quintile — and metastatic prostate cancer rates there are 11 percent higher, while overall prostate cancer incidence is 19 percent lower, plausibly reflecting inequitable access to asymptomatic PSA testing. Justice also complicates the details: some researchers argue FIT referral thresholds should differ for women and men, but the right answer depends on which measure of equity one chooses to prioritise, a value judgement that should be made transparently. Even overdiagnosis falls unevenly — introducing prostate screening for men in their seventies would generate more overdiagnosis among the most deprived, whose shorter life expectancy means more of them die of other causes before screening could ever help.

Autonomy poses a deeper philosophical problem. Public health typically overrides individual preferences for the collective good, while clinical medicine demands informed consent. Screening sits awkwardly between: society seeks consent before screening anyone, yet takes a paternalistic stance on what screening is offered at all, rarely considering the ethics of denying screening to those who want it. The authors suggest a more democratic division of labour, inspired by the Dutch model: expert committees could summarise evidence and uncertainties without issuing recommendations, forcing elected politicians to make the value-laden choices explicitly. Where experts disagree, politicians should decide. They even sketch a personalised option for prostate screening — inviting men aged 50 to 69 for triennial PSA testing without encouraging participation, letting personal risk tolerance guide the decision, much as oncology patients weigh their own treatment choices.

Feasibility, the authors stress, already governs screening policy whether it is admitted or not. FIT thresholds and age ranges are set by colonoscopy capacity; MRI-based prostate screening would demand vast new infrastructure of scanners and staff; and in low- and middle-income countries, cervical screening is constrained by the lack of facilities to triage screen-positive women and treat precancerous lesions. Public opinion constrains policy too — hence the continued offering of cervical screening at age 25 to women vaccinated against HPV as adolescents, despite their extremely low cervical cancer risk and the likelihood that screening does them more harm than good. The authors argue the public is mature enough to understand these trade-offs, provided they are communicated honestly.

Adaptability may be the most urgent principle in an era of artificial intelligence and liquid biopsies. Traditional screening trials are ruinously expensive — the National Lung Cancer Screening Trial cost 256 million dollars in 2002, roughly 400 million today — and a binary framework of full national implementation or complete rejection leaves no pathway for pragmatic pilots that generate evidence while delivering benefit. Multicancer detection tests sharpen the dilemma: by the time one test’s clinical utility is fully evaluated, the technology will be outdated, and trial designs that test each cancer type separately would require randomising millions of people. The authors call for publicly funded pilots designed to fill evidence gaps, with implementation beginning in health-deprived regions to address injustice rather than widen it. They are candid about the risks of permissiveness — a pilot ovarian screening programme before 2021 would have harmed some healthy women with false positives — but insist those harms and benefits could and should have been estimated in advance, and that any new decision-making system should itself be monitored and reformed if it fails.

The paper’s conclusion is disarmingly simple: presenting screening policy as a straightforward application of evidence-based medicine obscures profound ethical and political choices, and delaying a decision is itself a decision against change — one measured in preventable deaths, avoidable morbidity and widening inequality. As AI begins to exceed human radiologists and pathologists, quantifying future disease risk and optimising screening intervals, governance structures built around static population interventions and decade-long trials will be unable to evaluate products superseded every five years. Who decides, on what basis, and how quickly — the authors argue — are questions that can no longer be left unasked.

Subject of Research: Ethical and policy frameworks for cancer screening decision-making under uncertainty

Article Title: The clinical consequences of excessive caution: rethinking how cancer screening policy is made

Article References: Sasieni, P., & John, S. (2026). The clinical consequences of excessive caution: rethinking how cancer screening policy is made. eClinicalMedicine, Article 104188. https://doi.org/10.1016/j.eclinm.2026.104188

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104188

Keywords: cancer screening, screening policy, decision-making under uncertainty, health inequalities, prostate cancer screening, bowel cancer screening, multicancer detection tests, artificial intelligence, overdiagnosis, public trust, clinical, consequences

The article opens with a composite scenario that will feel familiar to many rheumatologists. A 40-year-old woman is referred for possible lupus after endorsing diffuse joint and muscle pain, headaches, fatigue, dry eyes and mouth, gastrointestinal distress, cognitive fog, and non-restorative sleep on a standardized review of systems. Her physical examination is entirely unremarkable: no synovitis, rash, ulcers, alopecia, edema, or neurologic deficits. Her antinuclear antibody titer is 1:160 with a dense fine speckled pattern, but antibodies to extractable nuclear antigens and double-stranded DNA are negative, complement levels are normal, and inflammatory markers are not elevated. Despite never meeting classification criteria for systemic lupus erythematosus, she carries the diagnosis in her record, has received hydroxychloroquine and repeated courses of glucocorticoids for flares, and has been counseled to delay pregnancy because of supposed disease activity. Years later, the label persists even after the medication is stopped for lack of benefit, and she has never been evaluated for or educated about fibromyalgia.

Chatterjee traces part of the problem to how modern medicine documents symptoms. Evaluation and Management guidelines introduced by the Centers for Medicare and Medicaid Services in 1995 and 1997 incentivized exhaustive checklist documentation over concise diagnostic synthesis, a shift the American College of Physicians later criticized for embedding clinically uninformative phrases such as a negative 10-point review of systems into routine notes purely to satisfy billing requirements. Within this environment of note bloat, the review of systems evolved from a focused diagnostic tool into an indiscriminate symptom inventory that can escalate concern for autoimmune disease. Yet autoimmune rheumatic diseases rarely announce themselves through diffuse symptom accumulation alone. Accurate diagnosis depends on coherent clinical phenotypes built from objective findings, such as clinical synovitis, characteristic rashes, Raynaud phenomenon, serositis, cytopenias, glomerulonephritis, inflammatory myopathy, or biopsy-proven organ involvement, accompanied by disease-specific autoantibodies.

The statistical core of the argument is Bayesian. Systemic autoimmune rheumatic diseases are collectively uncommon in the general population, whereas fibromyalgia and related central sensitization syndromes affect roughly 2 to 4 percent of adults. In a low-prevalence setting, the pretest probability of autoimmune disease is low even among highly symptomatic patients, and adding more non-specific findings does little to move it. Fatigue, diffuse pain, sleep disturbance, paresthesias, and cognitive complaints are intentionally sensitive but weakly specific symptoms that occur frequently in the absence of autoimmune disease, so each additional low-specificity finding contributes negligible diagnostic information and may obscure meaningful signals. By contrast, objective inflammatory and organ-specific findings substantially increase post-test probability. Failing to account for these base rates, the author contends, predictably produces diagnostic error.

Several well-described cognitive biases amplify the problem. Availability bias raises suspicion for autoimmune disease because these conditions are memorable, complex, and emphasized during training. Base-rate neglect leads clinicians to overestimate the likelihood of rare diseases. Anchoring bias occurs when an early finding, particularly a positive antinuclear antibody, dominates subsequent reasoning even as contradictory evidence accumulates. Once an autoimmune label is introduced, diagnostic momentum sustains it: subsequent clinicians inherit the diagnosis, interpret new symptoms through that lens, and hesitate to reverse course. Electronic health records and templated documentation perpetuate diagnoses long after their evidentiary basis has eroded, with problem-list clutter and indiscriminate review-of-systems templates reinforcing the appearance of chronic multisystem disease. The author also acknowledges that these errors are psychologically compelling, because both clinicians and patients often seek explanations proportional to the magnitude of suffering, and a multisystem autoimmune label can feel validating even when it is inaccurate.

Antinuclear antibody testing illustrates how bias and inappropriate test utilization intersect. Although the test is highly sensitive across autoimmune rheumatic diseases, it lacks specificity and performs poorly as a screening tool in low-prevalence populations. Low-titer antinuclear antibody, at 1:80 or below by indirect immunofluorescence, is present in 14 to 25 percent of healthy individuals and 10 to 12 percent of patients with fibromyalgia. Outside appropriate clinical contexts, the positive predictive value of the test for lupus is often in the single digits. When testing is ordered in low-probability settings, a positive result frequently triggers cascades of additional serologic work, incidental abnormalities, patient anxiety, and provisional labels such as possible lupus or undifferentiated connective tissue disease. Autoantibodies alone do not establish causality and may coexist with symptoms arising from entirely different processes. The test does retain real utility through its high negative predictive value, approaching 98 percent for excluding lupus, reflecting sensitivity of roughly 95 percent for systemic lupus erythematosus and systemic sclerosis and 85 to 90 percent for Sjögren syndrome and mixed connective tissue disease.

Central sensitization syndromes complicate this picture because they produce real, often disabling symptoms without consistent structural or inflammatory correlates. The absence of a definitive biomarker can create discomfort around diagnostic uncertainty, prompting clinicians to substitute non-specific serologic abnormalities as explanatory anchors. Chatterjee argues that diagnosing fibromyalgia should be viewed not as diagnostic failure but as a conclusion grounded in probability, pattern recognition, and outcome-based evidence, and that recognizing symptom amplification rather than inflammation is a learned clinical skill requiring deliberate teaching. Social determinants of health, including chronic stress, early-life adversity, repetitive occupational strain, nutritional deficiencies, and socioeconomic disadvantage, can amplify pain processing and produce diffuse symptoms resembling fibromyalgia, broadening diagnostic reasoning beyond autoimmune paradigms. Fibromyalgia also commonly coexists with confirmed autoimmune disease, occurring in about 25 percent of rheumatoid arthritis, 30 percent of lupus, and up to 50 percent of primary Sjögren’s syndrome cases, where its symptom burden can be mistaken for inflammatory flare.

Fear of missing early lupus often drives ongoing surveillance, but longitudinal data are reassuring. In patients with fibromyalgia, including those with positive antinuclear antibodies, the risk of developing lupus is approximately 0.0027 percent per year, similar to the general population, and low-titer antinuclear antibody does not predict future autoimmune rheumatic disease. Among antibody-positive individuals without established disease, progression is uncommon and is driven by evolving objective clinical features, disease-specific autoantibodies, and interferon signatures rather than antibody positivity alone. Serial autoantibody testing adds little value in the absence of new clinical findings. The author notes that some diseases, including the spondyloarthritis spectrum, polymyalgia rheumatica, large- and medium-vessel vasculitis, and Still’s disease, are seronegative, so diagnosis in early or atypical presentations requires longitudinal reassessment rather than point-in-time evaluation.

The harms of misdiagnosis are not benign. Patients labeled with autoimmune disease may face prolonged anxiety, repeated testing, unnecessary referrals, and exposure to glucocorticoids, hydroxychloroquine, biologics, and other immunosuppressants that carry metabolic, skeletal, ophthalmologic, infectious, and financial risks without addressing the true driver of symptoms. Life decisions around pregnancy, employment, insurance, and identity may be altered, disproportionately affecting women. At the systems level, indiscriminate testing and referrals increase costs without improving outcomes. Clear communication is essential to the solution: framing fibromyalgia as a disorder of pain processing rather than tissue damage helps validate symptoms and explain the lack of response to immunosuppression, while diagnostic restraint should be presented as probability-based rather than inattentive. The article closes with principles for generalists, including reserving screening labs for targeted indications, refusing to let isolated low-titer results drive labeling, diagnosing functional disorders with validated criteria rather than by exclusion, and favoring longitudinal clinical assessment over serial laboratory testing. A pan-positive review of systems, the author concludes, should prompt diagnostic restraint rather than escalation, because precision in diagnosis requires resisting serologic noise and returning to reasoning grounded in probability, pattern recognition, and humility.

Subject of Research: Diagnostic anchoring on positive autoimmune serologies and its role in misdiagnosis of systemic autoimmune rheumatic disease in polysymptomatic patients

Article Title: Diagnostic Anchoring on Positive Autoimmune Serologies in Polysymptomatic Patients

Article References: Chatterjee, S. (2026). Diagnostic Anchoring on Positive Autoimmune Serologies in Polysymptomatic Patients. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10727-6

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10727-6

Keywords: diagnostic anchoring, antinuclear antibody, autoimmune serologies, base-rate neglect, fibromyalgia, central sensitization, systemic lupus erythematosus, misdiagnosis, iatrogenic harm, overdiagnosis, rheumatology, low-value care